Aclaris Therapeutics Inc

ACRS remains in a Stage 2 advancing regime with higher highs and rising EMAs intact. The medium-term bias is bullish, reinforced by price above key moving averages despite exhaustion signals. Near-term, a Bullish Exhaustion pattern and RSI pullback indicate momentum is easing. Price is consolidating just above the 9/20 EMA band, making timing unfavorable now. Wait for a pullback into rising EMA support before initiating any long exposure.

• ↑FDA Fast Track designation accelerates modzatinib approval pathway.
• ↑Analysts rate Buy with $11.33 average target (~60% upside).
• ↓Net margin –921% and earnings yield –1.25 reflect deep losses.